
DAVID FINDLAY

SPEAKER AT:

THE GLOBAL THREAT OF ANTIMICROBIAL RESISTANCE SCIENCE FOR INTERVENTION



November, 5th, 6th and 7th, 2013, Barcelona

David Findlay, Global Commercial Lead at [GlaxoSmithKline](http://www.gsk.com), London, United Kingdom

David Findlay has held a number of country and global commercial roles in GSK. He has been involved in the infectious disease area for the past 12 years working alongside R&D colleagues in strategy development as well as providing commercial input on new pipeline antibiotics. Recently, David has been working with other industry stakeholders to look at a new commercial model for incentivising investment in antibacterial R&D, including acting as deputy industry co-ordinator for EFPIA on the IMI ND4BB initiative Topic 4: Driving re-investment in R&D and the responsible use of new antibiotics.

B-DEBATE IS AN INITIATIVE OF:



WITH THE COLLABORATION OF:

